社区

Kintara Therapeutics, Inc.’s KTRA shares surged 63.4% on Apr 3 after the company inked a definitive merger agreement with Florida-based privately-held company, TuHURA Biosciences Inc. Per the agreement, KTRA will merge into TuHURA to form a new company aimed at developing late-stage oncology candidates.The combined company will operate under the name of TuHURA Biosciences, Inc., and trade in the Nasdaq stock exchange under the ticker symbol "HURA.". Per the agreement, Kintara equity holders are expected to collectively own up to approximately 2.85%, or 5.45%, including shares underlying the contingent value rights of the common stock of the combined company on a pro forma fully diluted basis. Meanwhile, equity holders of TuHURA are eligible to collectively own approximately 97.15%, or 94.55%, taking the distribution of the CVR shares, of the common stock of the combined company on a pro forma fully diluted basis after the merger is completed.The newly formed company will focus on adva